RxDoctor Payments DataLook up a doctor →

Edward Evans, MD

Interventional Cardiology · Phoenix, AZNPI 1083799985

Payments from drug & device makers

$36,374in general payments, 2019–2025

Across 860 payments — averaging $42.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$9K
  • Medtronic$7K
  • Biotronik Inc.$4K
  • AstraZeneca$3K
  • Kestra Medical Technology Services, Inc.$2K
  • Novartis$2K
  • plus $10K from 41 others

What the payments were for

  • Consulting fees$5,21314%
  • Speaking & faculty fees$1,9505%
  • Travel & lodging$2,5637%
  • Food & beverage$26,56773%
  • Education$820%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,374 in reported general payments places this provider in the 70th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$847,886
Medicare patients
696
Services billed
4,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban254$282,745
EliquisApixaban236$279,608
FarxigaDapagliflozin Propanediol219$248,053
EntrestoSacubitril/Valsartan74$93,740
Repatha SureclickEvolocumab104$65,309
BrilintaTicagrelor69$62,467
VascepaIcosapent Ethyl32$18,055
DapagliflozinDapagliflozin Propanediol26$12,896
Atorvastatin Calcium479$4,537
Metoprolol Succinate203$2,701
Rosuvastatin Calcium284$2,689
Ezetimibe137$2,430
Losartan Potassium267$2,427
Chlorthalidone137$2,383
Amiodarone Hcl98$2,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$3,438$310,519288 claims
Johnson & JohnsonXarelto$932$282,745254 claims
PfizerEliquis$383$279,608236 claims
NovartisEntresto$1,850$93,74074 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →